Analyst Ratings for Cytokinetics (CYTK) [Buys]
CYTK Rating Summary
CYTK Price Target Summary
- Highest: $4.00 (Canaccord Genuity)
- Lowest: $2.00 (Dawson James)
- Average: $3.30
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$3.30 (+184.5%)
Avg. $ Target:
$3.30 (+184.5%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/4/2013 | Piper Jaffray | New Coverage | Overweight (N/A) |
4.00 (N/A) |
0.70 | 1.16 | 65.71% | Details |
| 11/27/2012 | Dawson James | Downgrade | Market Outperform (N/A) |
2.00 (N/A) |
0.67 | 1.16 | 73.13% | Details |
| 8/1/2012 | Cowen | New Coverage | Outperform (N/A) |
N/A (N/A) |
0.69 | 1.16 | 68.12% | Details |
| 7/2/2012 | Needham & Company » Updated 4/2/2013 |
New Coverage | Buy (N/A) |
2.50 (N/A) |
0.64 | 1.16 | 81.25% | Details |
| 10/13/2011 | Rodman & Renshaw | New Coverage | Market Outperform (N/A) |
4.00 (N/A) |
1.22 | 1.16 | -4.92% | Details |
